We develop innovative treatments for certain indications and improve the performance of existing approved products, leveraging on our proprietary technology platforms. These enhanced products fulfill unmet medical needs, and they will be filed with FDA utilizing 505(b)(2) regulatory pathway.

Traditionally, the company derives its revenue from R&D services and on generic product milestones. Going forward, we envision majority of the our revenue will be coming from FDA and CFDA approved product sales (generic product revenue for the near term and branded product revenue for the mid/long term).

There are 3 programs undergoing Ph2/Ph3 clinical trials, one of which is an orphan drug product (FDA designated), two of which are innovative in nature as the only treatment available in the market place.

The company also has 10+ pipeline products at various stages of development.